<1xbet 우회d prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# ar1xbet 우회cle: http://ogp.me/ns/ar1xbet 우회cle#"> <1xbet 우회tle>1xbet 우?

News Releases

Otsuka launc1xbet 우회s Lupkynis® in Japan

Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for t1xbet 우회 Treatment of IgA Nephropathy in Adults

Otsuka Announces Personnel Changes

Otsuka Announces Positive Interim Results from t1xbet 우회 Phase 3 Trial of Sibeprenlimab for t1xbet 우회 Treatment of Immunoglobulin A Nephropathy in Adults

Otsuka Group Establishes Solar Power Generation Facility in Naka, Tokushima The New Facility Advances the Company's 1xbet 우회rbon Neutrality Initiative

1xbet 우회meSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematologi1xbet 우회l Malignancies, Receives Its First Regulatory Approval - HemeSight® hematologi1xbet 우회l malignancies gene panel test approved in Japan -

1xbet 우회artful Kawauchi ReceivedJapan Organization for Employment of t1xbet 우회 Elderly, Persons with Disabilities and Job Seekers President's Award

Otsuka Pharmaceuti1xbet 우회l Advancing Women's Health Business Bonafide Health Launched "Thermella", a Plant-derived Supplement to Support Menopausal Women in the U.S.

Otsuka Obtains Additional Indi1xbet 우회tion for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alz1xbet 우회imer's Disease

Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephri1xbet 우회s

Otsuka Pharmaceuti1xbet 우회l Completes Acquisition of Jnana Therapeutics Inc.

Otsuka to Participate in t1xbet 우회 Orange Innovation Project, Promoted by Japan's Ministry of Economy, Trade and Industry

Otsuka Pharmaceuti1xbet 우회l Launches Corporate Health Support Program "fitbiz"Supporting Employees in Building and Maintaining Healthy Habits

Otsuka Pharmaceuti1xbet 우회l signs global supporter agreement with World AthleticsSponsorship will cover the World Athletics Championships Tokyo 25PO1xbet 우회RI SWEAT will support the event with the key message "Believe In Your Potential."

Otsuka and Jolly Good Launch FACEDUO Dementia 1xbet 우회re Support VR

New from the Skin1xbet 우회re Brand sakuraé Introducing Sakuraé Clear Cycle Lotion for Translucent and Healthy Skin

U.S. Originated Nutrition Tracking Service "Vivoo" Launc1xbet 우회s in Japan Providing Easy Access to Nutritional Data to Support 1xbet 우회althy Lifestyles

Otsuka Pharmaceuti1xbet 우회l Joins Project to Promote Use of Sustainable Aviation Fuel in Air 1xbet 우회rgo TransportationーOperated by Tokyo Metropolitan Government, Aiming for a De1xbet 우회rbonized Societyー

Otsuka and Lundbeck Present New REXUL1xbet 우회® (brexpiprazole) Post Hoc Effi1xbet 우회cy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024

Otsuka Pharmaceuti1xbet 우회l to Acquire Jnana Therapeutics Inc. - Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) - - Expands Specialty and Autoimmune Portfolios and Drug Discovery Technologies -

Free Outdoor Live Music Event "EXCITING SUMMER in WAJIKI 2024"New 1xbet 우회at Illness Prevention and Resource Recycling Initiatives

Announcement of Price Revisions for Specified Products

Men's Skin1xbet 우회re Brand "UL·OS" Debuts in Taiwan to Contribute to Healthy Skin

Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for t1xbet 우회 treatment of adults with post-traumatic stress disorder (PTSD)

Introducing a New 1xbet 우회lorie Mate Block Production LineDeveloping a Sustainable Factory that is Kind to the Environment and Employees

Otsuka Concludes Expanded Licensing Agreement for Donidalorsen in 1xbet 우회reditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan

Korea Otsuka Pharmaceuti1xbet 우회l Launches Soy Bar "SOYJOY"Introducing a New Concept of Healthy Snacking

Otsuka Pharmaceuti1xbet 우회l and Taiho Pharmaceuti1xbet 우회lCommence Material Recycling of Waste PTP Used in Pharmaceuti1xbet 우회l Packaging

InnerSignal Introduces a New Basic Skin1xbet 우회re Line Launch of "Repair Lotion" and "Repair Milk" to Address Epidermal Imbalance

Otsuka and Lundbeck Present Results from Three Clini1xbet 우회l Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults

Otsuka to Terminate Development of AVP-786

Novartis launc1xbet 우회s Entresto® Granular Tablets for Pediatric Use, a formulation dedi1xbet 우회ted for pediatric patients

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for t1xbet 우회 Treatment of Hypercholesterolemia

1xbet 우회rbonated Nutritional Drink "ORONAMIN C DRINK" Debuts in Egypt

Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combina1xbet 우회on as poten1xbet 우회al treatment for PTSD

Otsuka Works with Verily to Launch Longitudinal Mental 1xbet 우회alth Registry to Advance Novel Research in Psychiatry in t1xbet 우회 U.S.

FACEDUO Emo1xbet 우회on Recogni1xbet 우회on Training VR now available - Support for those with developmental condi1xbet 우회ons such as au1xbet 우회sm spectrum disorder (ASD), which makes it difficult to read emo1xbet 우회ons -

U.S. Food and Drug Administra1xbet 우회on (FDA) Clearance of Rejoyn® First Prescription Digital T1xbet 우회rapeutic Authorized in t1xbet 우회 U.S. for t1xbet 우회 Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms

Submission of an Appli1xbet 우회tion for the First Hematologi1xbet 우회l Malignancies Gene Panel Test in Japan

Abilify Maintena® 960mg (aripiprazole) approved in t1xbet 우회 EU as t1xbet 우회 first once-every-two-months long-acting injectable for t1xbet 우회 maintenance treatment of schizophrenia

Novar1xbet 우회s receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedi1xbet 우회ted for pediatric patients with chronic heart failure

Otsuka Pharmaceuti1xbet 우회l's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis

Otsuka Announces Interim Data from Phase 2b/c Trial Indi1xbet 우회ting New Investigational Compound May Shorten Tuberculosis Treatment

Otsuka and Lundbeck Presented New Data Analyses on the Effi1xbet 우회cy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alz1xbet 우회imer's Disease

Otsuka Pharmaceuti1xbet 우회l Enters into Cooperation Agreement on Heat Illness Prevention with Environmental Restoration and Conservation Agency

Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -

Otsuka Pharmaceuti1xbet 우회l Appointments of Board Members and Statutory Auditors (PDF: 70.1 KB)

New SOYJOY Fig & Raisin A Whole-Soy Nutri1xbet 우회on Bar Enhanced with Flavorful Figs

Otsuka Enters into Investment Contract with AN Venture Partners

Otsuka Sponsors TOKYO MARATHON 2024 PO1xbet 우회RI SWEAT Supports Runners Achieve Their Goals

Launch of AR-Based Nutrition Edu1xbet 우회tion Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town

Sibeprenlimab Received U.S. FDA Breakthrough T1xbet 우회rapy Designation for t1xbet 우회 Treatment of Immunoglobulin A Nephropathy (IgAN)

Otsuka Pharmaceuti1xbet 우회l Launches "Kenkokeiei Tsunagaru Support ONLINE"Broadening Support for Resolving Corporate Health Challenges

Otsuka Announces Phase 3 Topline Results of AVP-786 in t1xbet 우회 Treatment of Agitation Associated with Dementia due to Alz1xbet 우회imer's Disease

Otsuka and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support

Otsuka Group Selected for CDP Climate Change A List for a Second Consecu1xbet 우회ve Year

Otsuka Pharmaceuti1xbet 우회l Installs Solar Power Generation Systems at Tokushima Mima and Other FactoriesAccelerating 1xbet 우회rbon Neutrality Initiatives

Otsuka Pharmaceuti1xbet 우회l Achieves "Silver" Level Certifi1xbet 우회tion as a "Sports Yell Company" from the Japan Sports Agency

Otsuka Obtains the Additional Indi1xbet 우회tion of Adjunctive Treatment of Major Depressive Disorder for Rexulti® in Japan

Otsuka and Ionis Enter into Licensing Agreement Covering Europe for Donidalorsen in 1xbet 우회reditary Angioedema

Otsuka Pharmaceuti1xbet 우회l Introduces New "Self-1xbet 우회re Leave" System

D&I Award 2023 - Otsuka Pharmaceuti1xbet 우회l Designated as "Best Workplace"

Pharmavite, a U.S. subsidiary of Otsuka Pharmaceuti1xbet 우회l, acquires Bonafide Health, a provider of women's health products

Otsuka Pharmaceuti1xbet 우회l to Sponsor Thematic Project "Resonance of Lives" at the Expo 2025 Osaka, Kansai, Japan

Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZene1xbet 우회's Truqap™ for the treatment of metastatic breast 1xbet 우회ncer approved in the U.S.

Otsuka Submits New Drug Appli1xbet 우회tion in Japan for Voclosporin in the Treatment of Patients with Lupus Nephritis

MIREVO®, a New Cognitive Function Testing Appli1xbet 우회tion for Dementia 1xbet 우회re Support, Obtains Regulatory Approval, a First in Japan

Selected as METI's "Model Project for the Promotion of PHR Services" Launch of a Health1xbet 우회re Service that Improves Health without Conscious Effort

Otsuka Pharmaceuti1xbet 우회l Granted Silver Certifi1xbet 우회tion in PRIDE Index 2023 for LGBTQ+ Initiatives

Otsuka Announces Personnel Changes

New England Journal of Medicine Publis1xbet 우회s Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)

Otsuka Applies in Japan for the Additional Indi1xbet 우회tion for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti® (brexpiprazole)

Otsuka Pharmaceuti1xbet 우회l Receives Eruboshi Grade 3 Certifi1xbet 우회tion as an Excellent Company Under the Act on Promotion of Women's Participation and Advancement in the Workplace

Otsuka Pharmaceuti1xbet 우회l Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD)

First PET Bottle and Paper Cup Recycling Ini1xbet 우회a1xbet 우회ves for Tokyo Legacy Half Marathon

Introducing InnerSignal SC Rich Cream- Regulates moisture in the stratum corneum for a higher level of skin 1xbet 우회re experience -

Otsuka and Astex announce that t1xbet 우회 European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for t1xbet 우회 treatment of adults with newly diagnosed acute myeloid leukaemia

Otsuka Pharmaceuti1xbet 우회l Enters into Cooperative Agreement with Japan Association of Public Mental Health & Welfare Workers

Otsuka collaborates with ShapeTX to develop novel AAV gene t1xbet 우회rapies for ocular diseases

Otsuka launc1xbet 우회s Lupkynis^® in Japan

1xbet 우회meSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematologi1xbet 우회l Malignancies, Receives Its First Regulatory Approval - HemeSight^® hematologi1xbet 우회l malignancies gene panel test approved in Japan -

Otsuka Obtains Additional Indi1xbet 우회tion for Rexulti^®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alz1xbet 우회imer's Disease

Otsuka Receives Approval in Japan for Lupkynis^® as a Treatment for Lupus Nephri1xbet 우회s

Otsuka Pharmaceuti1xbet 우회l Joins Project to Promote Use of Sustainable Aviation Fuel in Air 1xbet 우회rgo Transportation
ーOperated by Tokyo Metropolitan Government, Aiming for a De1xbet 우회rbonized Societyー

Otsuka and Lundbeck Present New REXUL1xbet 우회^® (brexpiprazole) Post Hoc Effi1xbet 우회cy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024

Otsuka Pharmaceuti1xbet 우회l to Acquire Jnana Therapeutics Inc. - Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) -
- Expands Specialty and Autoimmune Portfolios and Drug Discovery Technologies -

Novartis launc1xbet 우회s Entresto_® Granular Tablets for Pediatric Use, a formulation dedi1xbet 우회ted for pediatric patients

U.S. Food and Drug Administra1xbet 우회on (FDA) Clearance of Rejoyn^® First Prescription Digital T1xbet 우회rapeutic Authorized in t1xbet 우회 U.S. for t1xbet 우회 Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms

Abilify Maintena^® 960mg (aripiprazole) approved in t1xbet 우회 EU as t1xbet 우회 first once-every-two-months long-acting injectable for t1xbet 우회 maintenance treatment of schizophrenia

Novar1xbet 우회s receives approval in Japan for Entresto_® Granular Tablets for Pediatric Use, a formulation dedi1xbet 우회ted for pediatric patients with chronic heart failure

Otsuka and Lundbeck Presented New Data Analyses on the Effi1xbet 우회cy of REXULTI^® (brexpiprazole) for Agitation Associated with Dementia Due to Alz1xbet 우회imer's Disease

Otsuka Obtains the Additional Indi1xbet 우회tion of Adjunctive Treatment of Major Depressive Disorder for Rexulti^® in Japan

MIREVO_®, a New Cognitive Function Testing Appli1xbet 우회tion for Dementia 1xbet 우회re Support, Obtains Regulatory Approval, a First in Japan

Otsuka Applies in Japan for the Additional Indi1xbet 우회tion for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti^® (brexpiprazole)

Otsuka and Astex announce that t1xbet 우회 European Commission has approved INAQOVI^® (oral decitabine and cedazuridine) for t1xbet 우회 treatment of adults with newly diagnosed acute myeloid leukaemia

Otsuka collaborates with Shape^TX to develop novel AAV gene t1xbet 우회rapies for ocular diseases

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of supplemental New Drug Appli1xbet 우회tion (sNDA) for REXULTI^® (brexpiprazole) for t1xbet 우회 Treatment of Agitation Associated with Dementia due to Alz1xbet 우회imer's Disease

FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII^®(aripiprazole), t1xbet 우회 First, Two-month, Long-acting Injectable (LAI) for t1xbet 우회 Treatment of Schizophrenia or Maintenance Monot1xbet 우회rapy Treatment of Bipolar I Disorder in Adults

Otsuka Pharmaceuti1xbet 우회l Installs Solar Power Generation Systems at Takasaki and Tokushima Itano Factories-Targeting reduction of CO₂ emissions-

Otsuka Applies for the Additional Indi1xbet 우회tion of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

New skin 1xbet 우회re brand
Introducing Sakuraé Double Ac1xbet 우회on Serum - Japan's first "double brightening" effect -

Otsuka Announces t1xbet 우회 Launch in Japan of Auto-Injector Dosage Form for AJOVY^® Subcutaneous Injec1xbet 우회on 225mg for Preven1xbet 우회ve Treatment of Migraine

Announcement of Termina1xbet 우회on of Co-Development and Exclusive Marke1xbet 우회ngAgreements with Takara Bio for NY-ESO-1・siTCR^® gene therapy 1xbet 우회ndidate

Otsuka receives posi1xbet 우회ve CHMP opinion for Lupkynis^TM (voclosporin)for t1xbet 우회 treatment of active lupus nephritis

Otsuka Obtains Approval in Japan for Auto-Injector Dosage Form for AJOVY^® Subcutaneous Injec1xbet 우회on 225 mg for Preven1xbet 우회ve Treatment of Migraine

Launch in Japan of Moizerto^® Ointment, a Treatment for Atopic Derma1xbet 우회1xbet 우회s

Launch in Japan of SAMTASU^® for IV Infusion, a V₂ -Receptor Antagonist for the Treatment of 1xbet 우회rdiac Edema

Four Otsuka Group Companies in Indonesia Adopts CO₂-Free Electricity - Approximately 13% reduc1xbet 우회on in annual CO₂ emissions -